Physician profile
Ali Mohamad Sayed
NPI 1548410400
$5,446.56
in general payments reported to CMS, 2019-2025
55 companies · $1,804 in 2025
The $1,804 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $77.68 · 2022: $1,290 · 2023: $378 · 2024: $1,467 · 2025: $1,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.13 |
| Education | $221.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,532.02 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $289.68 | 2019-2025 | Lynparza, Enhertu |
| Pfizer INC. | $268.32 | 2019-2025 | |
| Janssen Biotech, INC. | $257.04 | 2023-2025 | Erleada, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $239.05 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $204.39 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.74 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Abbvie INC. | $171.34 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.64 | 2019-2024 | Opdualag |
| Karyopharm Therapeutics INC. | $117.28 | 2024-2025 | Xpovio |
| Seagen INC. | $99.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $88.60 | 2024 | Darzalex, Rybrevant, Erleada |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.01 | 2019 | |
| Genentech USA, INC. | $84.89 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Genzyme Corporation | $78.01 | 2024-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $76.26 | 2024-2025 | Reblozyl, Pomalyst |
| Alexion Pharmaceuticals, INC. | $70.89 | 2023-2025 | Ultomiris |
| Incyte Corporation | $69.23 | 2025 | Jakafi, Zynyz, Monjuvi |
| Tg Therapeutics, INC. | $68.29 | 2025 | |
| Aveo Pharmaceuticals, INC. | $68.00 | 2025 | |
| Eisai INC. | $67.90 | 2024-2025 | |
| Tempus Ai, INC | $67.13 | 2024 | |
| Exelixis INC. | $65.92 | 2020-2022 | |
| Lilly USA, LLC | $61.29 | 2023-2025 | Jaypirca, Retevmo, Verzenio |
| Eusa Pharma (US) LLC | $60.06 | 2019 | |
| Stemline Therapeutics INC. | $54.64 | 2023 | Orserdu |
| Pharmaessentia USA Corporation | $50.76 | 2023-2025 | Besremi |
| Beone Medicines USA, INC. | $45.90 | 2025 | Tevimbra |
| Jazz Pharmaceuticals INC. | $45.86 | 2024-2025 | |
| Emd Serono, INC. | $45.51 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $45.37 | 2023-2024 | Libtayo |
| Glaxosmithkline, LLC. | $42.35 | 2024 | Ojjaara |
| Servier Pharmaceuticals LLC | $42.14 | 2024-2025 | |
| Gilead Sciences, INC. | $39.27 | 2024 | |
| Sobi, INC | $35.13 | 2024 | |
| Legend Biotech USA INC. | $34.82 | 2025 | Carvykti |
| Array Biopharma INC | $31.51 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Deciphera Pharmaceuticals INC. | $30.13 | 2025 | Qinlock, Romvimza |
| Azurity Pharmaceuticals, INC. | $29.98 | 2025 | Vivimusta |
| Pharmacyclics LLC, An Abbvie Company | $29.66 | 2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $28.98 | 2025 | Xtandi |
| Beigene USA, INC. | $26.78 | 2023 | Brukinsa |
| Puma Biotechnology, INC. | $26.33 | 2025 | |
| Novocure INC. | $26.12 | 2025 | Optune Lua (Novottf-200t) |
| Immunogen, INC. | $23.73 | 2023 | Elahere |
| Bayer Healthcare Pharmaceuticals INC. | $22.94 | 2024 | |
| Genmab U.S., INC. | $22.72 | 2024 | Epkinly |
| Pharmacosmos Therapeutics INC. | $22.37 | 2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $20.95 | 2024 | Onivyde |
| Myriad Genetic Laboratories, INC. | $19.32 | 2025 | Myrisk |
| G1 Therapeutics, INC. | $18.02 | 2023 | Cosela |
| Apellis Pharmaceuticals, INC. | $16.39 | 2025 | Empaveli |
| Mirati Therapeutics, INC. | $15.32 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $15.20 | 2024 | Tavalisse, Rezlidhia |
| Coherus Oncology, INC. | $14.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Sayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.